NRF2-driven thiol metabolism creates a selective vulnerability to selenite
NRF2 hyperactivation caused by mutations in KEAP1 or NFE2L2 occurs in 20-30% of non-small cell lung cancers and confers therapy resistance. Here we show th
NRF2 hyperactivation caused by mutations in KEAP1 or NFE2L2 occurs in 20-30% of non-small cell lung cancers and confers therapy resistance. Here we show th